Saturday, June 1 - Press Briefings available Sunday 7AM

  • LBA2: Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
  • LBA3: Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
  • LBA4: Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
  • LBA5: Durvalumab ± tremelimumab as consolidation therapy for patients with limited- stage small-cell lung cancer (LS-SCLC): Results from the phase 3 ADRIATIC study.
  • LBA105: Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
  • LBA5505: Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.
  • LBA503: ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.
  • LBA1000: Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) of chemotherapy in patients (pts) with hormone receptor– positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) >0<1+ metastatic breast cancer (mBC): Primary results from DESTINY-Breast06.

Presenter: Christian U. Blank, MD, PhD Netherlands Cancer Institute (NKI-AVL)  

Abstract LBA2 Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Presenter: Joseph A. Greer, PhD Massachusetts General Hospital, Harvard Medical School

Abstract LBA3 Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.

Presenter: Suresh S. Ramalingam, MD, FASCO, FACP Emory University School of Medicine, Winship Cancer Institute

Abstract LBA4 Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.

Presenter: David R. Spigel, MD, FASCO Sarah Cannon Research Institute

Abstract LBA5 ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).

Suzanne Trudel, Princess Margaret Cancer Centre, Toronto, ON, Canada

LBA105: Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).

 

See also NEJM ORIGINAL ARTICLE

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

V. Hungria and Others

Presenter: Jean-Marc Classe, MD, PhD Nantes Université

Abstract LBA5505 Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.

Presenter: Tarah Jean Ballinger, MD Indiana University Simon Comprehensive Cancer Center

Abstract LBA503 ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.

Presenter: Giuseppe Curigliano University of Milan and European Institute of Oncology, IRCCS

Breast Cancer, Special Session/ Presentation and Discussion of LBA1000:

Abstract LBA1000 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Quicklinks

Kongressberichte
Kongresskalender
Aktuelles
Impressum
Kontakt

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2024. All Rights Reserved.
Datenschutzbestimmungen
You are using an outdated browser. The website may not be displayed correctly. Close